专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210137994A1 FECAL MATTER FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES 有权
公开(公告)号：US20210137994A1
公开(公告)日：2021-05-13
申请号：US16976055
申请日：2019-03-01
申请人： Academisch Medisch Centrum , Wageningen Universiteit
发明人： Max Nieuwdorp , Willem Meindert De Vos
IPC分类号： A61K35/37 , A61K9/00 , A61K45/06 , A61K35/74 , A61P37/06 , A61P3/10 , A61P5/14 , A61P5/38 , A61P17/06 , A61P17/00 , A61P19/02 , A61P1/00 , A61P11/06
摘要： The use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.

2. 发明授权

US11534465B2 Fecal matter for treatment of autoimmune diseases 有权
公开(公告)号：US11534465B2
公开(公告)日：2022-12-27
申请号：US16976055
申请日：2019-03-01
申请人： Academisch Medisch Centrum , Wageningen Universiteit
发明人： Max Nieuwdorp , Willem Meindert De Vos
IPC分类号： A61K35/37 , A61P5/38 , A61P17/06 , A61P11/06 , A61P37/06 , A61P17/00 , A61P19/02 , A61P3/10 , A61P1/00 , A61P5/14 , A61K9/00 , A61K35/74 , A61K45/06
摘要： The use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.

3. 发明申请

US20160317589A1 METHOD FOR PREVENTING AND/OR TREATING INSULIN RESISTANCE 有权
标题翻译：用于预防和/或治疗胰岛素抵抗的方法
公开(公告)号：US20160317589A1
公开(公告)日：2016-11-03
申请号：US15207335
申请日：2016-07-11
申请人： Academisch Medisch Centrum , Caelus Pharmaceuticals B.V.
发明人： Max Nieuwdorp , Willem Meindert De Vos
IPC分类号： A61K35/74 , A23K10/16 , A23L2/52 , A61K9/00 , A23L33/135
CPC分类号： A61K35/74 , A23K10/16 , A23L2/52 , A23L29/065 , A23L33/135 , A23V2002/00 , A61K9/0095 , A61K35/744 , A61K2035/11 , A23V2200/3204 , A23V2200/328 , A23V2200/332
摘要： Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
摘要翻译：描述了使用Eubacterium hallii et rel。和/或粪产碱杆菌等，以及包含这些细菌作为药物的药物，食品或饲料组合物，特别是用于预防和/或治疗胰岛素抵抗和/或胰岛素抵抗相关并发症如代谢综合征，血脂异常和2型糖尿病，以及内分泌疾病中的胰岛素抵抗（例如，1型糖尿病肥胖受试者，库兴氏病和脂肪营养不良综合征），还描述了一种预防和/或治疗胰岛素抵抗和/或胰岛素抵抗的方法相关的并发症如血脂异常和2型糖尿病以及在有需要的受试者中的内分泌疾病（例如，1型糖尿病的肥胖受试者，库兴氏症和脂肪营养不良综合征）中的胰岛素抵抗，该方法包括增加 Eubacterium hallii et rel。和/或Alcaligenes faecalis et rel。在小肠中的水平。

4. 发明授权

US09623055B2 Method for preventing and/or treating insulin resistance 有权
公开(公告)号：US09623055B2
公开(公告)日：2017-04-18
申请号：US15207335
申请日：2016-07-11
申请人： Academisch Medisch Centrum , Caelus Pharmaceuticals B.V.
发明人： Max Nieuwdorp , Willem Meindert De Vos
IPC分类号： A01N63/00 , A61K35/74 , A23L2/52 , A61K35/744 , A23L29/00 , A23L33/135 , A23K10/16 , A61K9/00 , A61K35/00
CPC分类号： A61K35/74 , A23K10/16 , A23L2/52 , A23L29/065 , A23L33/135 , A23V2002/00 , A61K9/0095 , A61K35/744 , A61K2035/11 , A23V2200/3204 , A23V2200/328 , A23V2200/332
摘要： Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.

5. 发明申请

US20180353552A1 BACTERIA-COMPRISING COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING GASTROINTESTINAL, METABOLIC AND/OR OTHER DISEASES 审中-公开
公开(公告)号：US20180353552A1
公开(公告)日：2018-12-13
申请号：US15542311
申请日：2016-01-08
申请人： WAGENINGEN UNIVERSITEIT
发明人： Willem Meindert De Vos , Thi Phuong Nam Bui
IPC分类号： A61K35/741 , A61K45/06 , A61P35/00 , C12R1/01 , A61P1/04
CPC分类号： A61K35/741 , A61K45/06 , A61P1/04 , A61P35/00 , C12R1/01
摘要： The disclosure is concerned with a novel human intestinal isolate capable of converting L-lysine into butyrate and/or of converting fructose-lysine into butyrate. The novel isolate can be used as a probiotic or supplement to promote production of butyrate in the GI tract, thereby preventing and/or treating conditions or diseases that benefit from the production of butyrate. Additionally, the isolate may prevent and/or treat conditions or diseases caused by an excess of pathogenic bacteria in the GI tract, mediated by L-lysine, or mediated by fructose-lysine or other advanced glycation end products.

6. 发明授权

US11466057B2 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status 有权
公开(公告)号：US11466057B2
公开(公告)日：2022-10-11
申请号：US16916459
申请日：2020-06-30
申请人： WAGENINGEN UNIVERSITEIT , UNIVERSITÉ CATHOLIQUE DE LOUVAIN
发明人： Clara Belzer , Willem Meindert De Vos , Patrice Daniel Cani
IPC分类号： A61K39/00 , C07K14/195 , A61P3/08 , A61P3/06 , C12N1/20 , A61K38/00
摘要： It has been found that an extracellular polypeptide derived from Akkermansia municiphila is capable of modulating and/or promoting gut mucosal immune system function and/or maintaining and/or restoring metabolic status and/or increasing the physical integrity of the gut mucosal barrier in a mammal. The polypeptide or host cells comprising such polypeptide may be employed to prevent and/or treat a variety of conditions that benefit from an increased physical integrity of the gut mucosal barrier and/or an improved gut mucosal immune system function and metabolic status.

7. 发明授权

US11452746B2 Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases 有权
公开(公告)号：US11452746B2
公开(公告)日：2022-09-27
申请号：US15542311
申请日：2016-01-08
申请人： Wageningen Universiteit
发明人： Willem Meindert De Vos , Thi Phuong Nam Bui
IPC分类号： A61K35/741 , A61K45/06 , C12N1/20 , A61P1/04 , A61P35/00 , C12R1/01
摘要： The disclosure is concerned with a novel human intestinal isolate capable of converting L-lysine into butyrate and/or of converting fructose-lysine into butyrate. The novel isolate can be used as a probiotic or supplement to promote production of butyrate in the GI tract, thereby preventing and/or treating conditions or diseases that benefit from the production of butyrate. Additionally, the isolate may prevent and/or treat conditions or diseases caused by an excess of pathogenic bacteria in the GI tract, mediated by L-lysine, or mediated by fructose-lysine or other advanced glycation end products.

8. 发明申请

US20210069263A1 BACTERIA-COMPRISING COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING GASTROINTESTINAL, METABOLIC AND/OR OTHER DISEASES 有权
公开(公告)号：US20210069263A1
公开(公告)日：2021-03-11
申请号：US17030196
申请日：2020-09-23
申请人： Wageningen Universiteit
发明人： Willem Meindert De Vos , Thi Phuong Nam Bui
IPC分类号： A61K35/741 , C12R1/01 , A61K45/06 , A61P1/04 , A61P35/00
摘要： Described is a novel human intestinal isolate capable of converting L-lysine into butyrate and/or of converting fructose-lysine into butyrate. The novel isolate can be used as a probiotic or supplement to promote production of butyrate in the GI tract, thereby preventing and/or treating conditions or diseases that benefit from the production of butyrate. Additionally, the isolate may prevent and/or treat conditions or diseases caused by an excess of pathogenic bacteria in the GI tract, mediated by L-lysine, or mediated by fructose-lysine or other advanced glycation end products.

9. 发明授权

US10738089B2 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status 有权
公开(公告)号：US10738089B2
公开(公告)日：2020-08-11
申请号：US15571175
申请日：2016-05-04
申请人： WAGENINGEN UNIVERSITEIT , UNIVERSITE CATHOLIQUE DE LOUVAIN
发明人： Clara Belzer , Willem Meindert De Vos , Patrice Daniel Cani
IPC分类号： A61K39/00 , C07K14/195 , C12N1/20 , A61P3/08 , A61P3/06 , A61K38/00
摘要： It has been found that an extracellular polypeptide derived from Akkermansia municiphila is capable of modulating and/or promoting gut mucosal immune system function and/or maintaining and/or restoring metabolic status and/or increasing the physical integrity of the gut mucosal barrier in a mammal. The polypeptide or host cells including such polypeptide may be employed to prevent and/or treat a variety of conditions that benefit from an increased physical integrity of the gut mucosal barrier and/or an improved gut mucosal immune system function and metabolic status.

10. 发明授权

US11426436B2 Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases 有权
公开(公告)号：US11426436B2
公开(公告)日：2022-08-30
申请号：US17030196
申请日：2020-09-23
申请人： Wageningen Universiteit
发明人： Willem Meindert De Vos , Thi Phuong Nam Bui
IPC分类号： A61K35/741 , A61K45/06 , C12N1/20 , A61P1/04 , A61P35/00 , C12R1/01
摘要： Described is a novel human intestinal isolate capable of converting L-lysine into butyrate and/or of converting fructose-lysine into butyrate. The novel isolate can be used as a probiotic or supplement to promote production of butyrate in the GI tract, thereby preventing and/or treating conditions or diseases that benefit from the production of butyrate. Additionally, the isolate may prevent and/or treat conditions or diseases caused by an excess of pathogenic bacteria in the GI tract, mediated by L-lysine, or mediated by fructose-lysine or other advanced glycation end products.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式